In a review published in the journal Genes & Diseases, researchers from ICMR-National Institute of Nutrition (NIN), advocate for the repurposing of non-cancer drugs to target elusive cancer stem cells (CSCs). By focusing on drugs that are already approved and have established safety records for other conditions, this strategy offers a more immediate and safer avenue to innovate cancer therapy.
Leave A Comment